Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

Table 3 Exposure to rituximab during the study for all patients

	Infusion 1	Infusion 2	Infusion 3	Infusion 4
Received infusion	351^a	341^a	290^b	278
Infusion at the faster rate	NA	337	289	278
Completed 1000 mg^c	338	333	288	277
Total infusion hours
n	338	333	288	277
Mean (SD)	4.4 (0.3)	2.0 (0.1)	2.1 (0.3)	2.0 (0.1)
Range	4.1-6.4	1.8-3.2	1.9-4.3	1.9-2.4
> 2.5 h	338 (100%)	5 (1.5%)	12 (4.2%)	0
> 4.5 h	41 (12.1%)	0	0	0

NA, not applicable; SD, standard deviation. ^aInfusion rate and dose could not be determined for 4 patients because the site failed to record the infusion volume. Of these 4 patients, 3 at Day 168 and 2 at Day 182 received rituximab at the faster rate. ^bRituximab was administered at the standard infusion rate in 1 patient. ^cRituximab dose was derived from the sum of the volume received at each segment. To account for truncation errors, the derived dose of 970 mg or larger was considered as completed 1000 mg.

ISSN: 1471-2474